Image Place holder

Sungjune Kim, MD, PhD


Specialty: Radiation Oncology
Program: Radiation Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

As the section chief for hematologic malignancy in the department of radiation oncology, Dr. Kim's clinical interests are treatment of patients with lymphoma and leukemia with radiation therapy. He is conducting a number of clinical research projects to improve management of lymphoma patients. Additionally, he has non-site specific interest in combining radiation therapy with immunotherapy, in particular melanoma, Merkel cell carcinoma and CNS malignancies.

Education & Training

Board Certification:

  • Radiation Oncology

Residency:

  • H. Lee Moffitt Cancer Center/USF - Radiation Oncology

Medical School:

  • Vanderbilt University - MD, PhD
Participating Trials

CLINICAL TRIAL 18786
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18395
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma
Condition: Malignant Hematology
Intervention: G100; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 17978
A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) with MK-3475 and Bevacizumab in Patients with Recurrent High Grade Gliomas
Condition: Neurologic Oncology
Intervention: Avastin (Bevacizumab); Bevacizumab; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18596
A Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy
Condition: Breast
Intervention: Not Applicable
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Strom T, Harrison LB, Giuliano AR, Schell MJ, Eschrich SA, Berglund A, Fulp W, Thapa R, Coppola D, Kim S, Frakes J, Foekens J, Mulé JJ, Torres-Roca JF. Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer. 2017 Oct;84:304-314. Pubmedid: 28863385.
  • Ahmed KA, Grass GD, Creelan B, Gray J, Kim S, Dilling TJ, Antonia SJ, Perez BA. Tolerability and Safety of Thoracic Radiation and Immune Checkpoint Inhibitors Among Patients with Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 May;98(1):224. Pubmedid: 28586976.
  • Caudell JJ, Torres-Roca JF, Gillies RJ, Enderling H, Kim S, Rishi A, Moros EG, Harrison LB. The future of personalised radiotherapy for head and neck cancer. Lancet Oncol. 2017 May;18(5):e266-e273. Pubmedid: 28456586.
  • Ahmed KA, Kim S, Arrington J, Naghavi AO, Dilling TJ, Creelan BC, Antonia SJ, Caudell JJ, Harrison LB, Sahebjam S, Gray JE, Etame AB, Johnstone PA, Yu M, Perez BA. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol. 2017 Jun;133(2):331-338. Pubmedid: 28466250.
  • Ahmed KA, Kim S, Harrison LB. Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma Management. Surg Oncol Clin N Am. 2017 Jul;26(3):515-529. Pubmedid: 28576186.
  • Strom T, Naghavi AO, Messina JL, Kim S, Torres-Roca JF, Russell J, Sondak VK, Padhya TA, Trotti AM, Caudell JJ, Harrison LB. Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck. Head Neck. 2017 Jan;39(1):48-55. Pubmedid: 27300153.
  • Abuodeh Y, Ahmed K, Echevarria M, Naghavi A, Grass GD, Robinson TJ, Tomblyn M, Shah B, Chavez J, Bello C, El-Haddad G, Harrison L, Kim S. Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. Ther Adv Hematol. 2017 Apr;8(4):129-138. Pubmedid: 28491264. Pmcid: PMC5405899.
  • Strom T, Carr M, Zager JS, Naghavi A, Smith FO, Cruse CW, Messina JL, Russell J, Rao NG, Fulp W, Kim S, Torres-Roca JF, Padhya TA, Sondak VK, Trotti AM, Harrison LB, Caudell JJ. Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. Ann Surg Oncol. 2016 Oct;23(11):3572-3578. Pubmedid: 27251134.
  • Naghavi A, Johnstone P, Kim S. Clinical trials exploring the benefit of immunotherapy and radiation in cancer treatment: A review of the past and a look into the future. Curr Prob Cancer. 2016 Jan;40(1):38-67. Pubmedid: 26656977.
  • Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016 Dec;27(12):2288-2294. Pubmedid: 27637745.
  • Grass GD, Krishna N, Kim S. The immune mechanisms of abscopal effect in radiation therapy. Curr Prob Cancer. 2016 Dec;40(1):10-24. Pubmedid: 26612692.
  • Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Prob Cancer. 2016 Dec;40(1):25-37. Pubmedid: 26582738.
  • Kim S, Ramakrishnan R, Lavilla-Alonso S, Chinnaiyan P, Rao N, Fowler E, Heine J, Gabrilovich DI. Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immun. 2014 Oct;63(10):1009-1021. Pubmedid: 24943275. Pmcid: PMC4330093.
  • Dilling TJ, Extermann M, Kim J, Thompson LM, Yue B, Stevens CW, Antonia S, Gray J, Williams C, Haura E, Pinder-Schenck M, Tanvetyanon T, Kim S, Chiappori A. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Nov;90(4):828-833. Pubmedid: 25216856.